Bio-Techne Corporation logo

Bio-Techne Corporation

TECH

NASDAQHealthcareBiotechnology

Previous close

$72.32

+$0.04 · +0.06%

Aug 21, 4:00 PM ET

TECH company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

48

Fair Value

Momentum

62

Gaining

Sentiment

58

Mixed

Risk resilience

59

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Kim Kelderman
Listed since
Feb 9, 1989
Employees
3,000

Market position

Day range

Current $72.32

52-week range

Current $72.32

Open
$72.33
Previous close
$72.28
Volume
3.96M
0.92× average
Average volume
4.28M
Average daily volume
Market cap
11.32B USD
Beta
1.28
Market reference 1
50-day average
$68.8666
+5.01% above average
200-day average
$60.3522
+19.83% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
11.04B USD
P/E (TTM)
61.81×
P/B (TTM)
5.35×
P/S (TTM)
9.32×
EV / EBITDA
32.15×
Earnings yield
1.65%
Free cash flow yield
2.39%
Dividend yield
0.44%

Profitability & efficiency

Gross margin
65.77%
Operating margin
20.73%
Net margin
14.97%
Return on equity
8.63%
Return on assets
7.03%
Return on invested capital
7.81%

Financial health

Debt / equity
0.13×
Current ratio
4.55×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends75%50%25%-0%Gross margin, FY2022: 68.42%Gross margin, FY2023: 67.72%Gross margin, FY2024: 66.41%Gross margin, FY2025: 64.80%Gross margin, FY2026: 65.77%Operating margin, FY2022: 26.83%Operating margin, FY2023: 26.30%Operating margin, FY2024: 17.83%Operating margin, FY2025: 8.38%Operating margin, FY2026: 20.73%Net margin, FY2022: 24.61%Net margin, FY2023: 25.10%Net margin, FY2024: 14.50%Net margin, FY2025: 6.02%Net margin, FY2026: 14.97%FY2022FY2023FY2024FY2025FY2026
Gross margin FY2022 68.42%. Gross margin FY2023 67.72%. Gross margin FY2024 66.41%. Gross margin FY2025 64.80%. Gross margin FY2026 65.77%. Operating margin FY2022 26.83%. Operating margin FY2023 26.30%. Operating margin FY2024 17.83%. Operating margin FY2025 8.38%. Operating margin FY2026 20.73%. Net margin FY2022 24.61%. Net margin FY2023 25.10%. Net margin FY2024 14.50%. Net margin FY2025 6.02%. Net margin FY2026 14.97%.

Income trends

Revenue

1.22B USD-0.38%

Operating income

251.89M USD+146.34%

Net income

181.86M USD+147.77%
Income trends across reported periods1.33B USD875.76M USD417.27M USD−41.22M USDRevenue, FY2022: 1.11B USDRevenue, FY2023: 1.14B USDRevenue, FY2024: 1.16B USDRevenue, FY2025: 1.22B USDRevenue, FY2026: 1.22B USDOperating income, FY2022: 296.59M USDOperating income, FY2023: 298.94M USDOperating income, FY2024: 206.69M USDOperating income, FY2025: 102.26M USDOperating income, FY2026: 251.89M USDNet income, FY2022: 272.05M USDNet income, FY2023: 285.26M USDNet income, FY2024: 168.11M USDNet income, FY2025: 73.4M USDNet income, FY2026: 181.86M USDFY2022FY2023FY2024FY2025FY2026
Revenue FY2022 1.11B USD. Revenue FY2023 1.14B USD. Revenue FY2024 1.16B USD. Revenue FY2025 1.22B USD. Revenue FY2026 1.22B USD. Operating income FY2022 296.59M USD. Operating income FY2023 298.94M USD. Operating income FY2024 206.69M USD. Operating income FY2025 102.26M USD. Operating income FY2026 251.89M USD. Net income FY2022 272.05M USD. Net income FY2023 285.26M USD. Net income FY2024 168.11M USD. Net income FY2025 73.4M USD. Net income FY2026 181.86M USD.
Metric (USD)FY2026FY2025FY2024FY2023FY2022
Revenue1.22B USD1.22B USD1.16B USD1.14B USD1.11B USD
Cost of goods sold415.97M USD429.36M USD389.34M USD366.89M USD349.1M USD
Gross profit799.07M USD790.27M USD769.73M USD769.82M USD756.5M USD
Research and development94.77M USD99.5M USD96.66M USD92.49M USD87.14M USD
Selling, general, and administrative452.42M USD415.1M USD393.32M USD352.44M USD339M USD
Operating expenses547.18M USD688.02M USD563.04M USD470.87M USD459.91M USD
Interest income3.89M USD3.32M USD3.41M USD794K USD
Interest expense5.41M USD8.51M USD15.74M USD11.22M USD11.31M USD
Depreciation and amortization97.36M USD109.9M USD111.71M USD107.24M USD101.07M USD
Operating income251.89M USD102.26M USD206.69M USD298.94M USD296.59M USD
Net income181.86M USD73.4M USD168.11M USD285.26M USD272.05M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
64%
7 beats, 4 misses, 0 met estimates
Average EPS surprise
+3.72%
11 comparable reports
Latest EPS result
0.52
Estimate 0.52 · Beat by 0.19%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates0.60.520.430.35Q1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25MissQ1 '26BeatQ2 '26MissQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 5, 2025: actual 0.42, estimate 0.386, surprise +8.75%, Beat. Q2 2025, reported May 7, 2025: actual 0.56, estimate 0.508, surprise +10.24%, Beat. Q3 2025, reported Aug 6, 2025: actual 0.53, estimate 0.499, surprise +6.13%, Beat. Q4 2025, reported Nov 5, 2025: actual 0.42, estimate 0.421, surprise -0.33%, Miss. Q1 2026, reported Feb 4, 2026: actual 0.46, estimate 0.43, surprise +6.98%, Beat. Q2 2026, reported May 6, 2026: actual 0.53, estimate 0.55, surprise -3.64%, Miss. Q3 2026, reported Aug 12, 2026: actual 0.52, estimate 0.519, surprise +0.19%, Beat. Q4 2026, reported Nov 4, 2026: actual —, estimate 0.46, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates338.47M316.83M295.18M273.54MQ1 '25MissQ2 '25MissQ3 '25BeatQ4 '25MissQ1 '26BeatQ2 '26MissQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 5, 2025: actual 297.03M USD, estimate 317.53M USD, surprise -6.46%, Miss. Q2 2025, reported May 7, 2025: actual 316.18M USD, estimate 325.45M USD, surprise -2.85%, Miss. Q3 2025, reported Aug 6, 2025: actual 316.96M USD, estimate 294.63M USD, surprise +7.58%, Beat. Q4 2025, reported Nov 5, 2025: actual 286.56M USD, estimate 291.32M USD, surprise -1.63%, Miss. Q1 2026, reported Feb 4, 2026: actual 295.88M USD, estimate 290.47M USD, surprise +1.86%, Beat. Q2 2026, reported May 6, 2026: actual 311.42M USD, estimate 316.11M USD, surprise -1.48%, Miss. Q3 2026, reported Aug 12, 2026: actual 321.19M USD, estimate 314.63M USD, surprise +2.09%, Beat. Q4 2026, reported Nov 4, 2026: actual —, estimate 292.06M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$65.78

9.04% downside
Past 12 months12-month forecastHigh $73.00Average $65.78Low $50.00

Rating distribution

26 ratings
Strong buy00%
Buy1246%
Hold1454%
Sell00%
Strong sell00%

TECH news

Corporate actions

Annual dividends per share

Cash distributions grouped by calendar year; partial years are marked.

$0.32

2025 complete year0.0% since 2021

2026 partial: $0.16

* Partial calendar year in the available dividend history.

Corporate action history

DividendUpcoming

Ex-dividend Aug 24, 2026

$0.08

Irregular

Record Aug 24, 2026 · Payment Sep 4, 2026

DividendUpcoming

Ex-dividend Aug 24, 2026

$0.08

Quarterly

Record Aug 24, 2026 · Payment Sep 4, 2026

Dividend

Ex-dividend May 18, 2026

$0.08

Quarterly

Record May 18, 2026 · Payment May 29, 2026

Dividend

Ex-dividend Feb 13, 2026

$0.08

Quarterly

Record Feb 16, 2026 · Payment Feb 27, 2026

Dividend

Ex-dividend Nov 17, 2025

$0.08

Quarterly

Record Nov 17, 2025 · Payment Nov 28, 2025

Dividend

Ex-dividend Aug 18, 2025

$0.08

Quarterly

Record Aug 18, 2025 · Payment Aug 29, 2025

TECH peers

ETFs holding TECH

Funds reporting this stock among their holdings, ordered by reported position size.

Continue in GoAI

Research TECH

research.disclaimer